Angiotensin II (Giapreza®): A Comprehensive Pharmacological and Clinical Monograph for the Management of Distributive Shock

Executive Summary

Angiotensin II, marketed under the brand name Giapreza®, is a synthetic formulation of the endogenous human peptide hormone that functions as a potent vasoconstrictor. This biotech therapeutic is indicated for adults with septic or other forms of distributive shock who remain hypotensive despite adequate fluid resuscitation and standard-of-care vasopressor therapy. Its approval marks a significant development in critical care medicine, introducing the first therapeutic agent that directly targets the renin-angiotensin-aldosterone system (RAAS) to restore vascular tone in shock states.

The primary mechanism of action involves agonism of the Angiotensin II Type 1 (AT1) receptor, leading to rapid and potent vasoconstriction and a subsequent increase in mean arterial pressure (MAP). Clinical evidence, principally from the pivotal ATHOS-3 trial, has robustly demonstrated its efficacy in achieving hemodynamic targets within minutes of administration, often allowing for a reduction in the dosage of concomitant catecholamine vasopressors. This catecholamine-sparing effect is a key therapeutic benefit, potentially mitigating the adverse effects associated with high-dose catecholamine use.

The principal safety concern associated with Angiotensin II therapy is a statistically significant increase in the risk of both arterial and venous thromboembolic events. This risk necessitates the concurrent administration of venous thromboembolism (VTE) prophylaxis. The drug's pharmacokinetic profile is characterized by an extremely short half-life of less than one minute, which allows for precise and rapid dose titration but mandates continuous intravenous infusion via a central line in an intensive care setting.

While Angiotensin II has not demonstrated a statistically significant mortality benefit in the overall population of patients with distributive shock, post-hoc analyses suggest improved survival in specific patient subgroups, particularly those with a hyper-reninemic state. This finding positions Giapreza not merely as a salvage therapy but as a potential first step toward a biomarker-guided, personalized approach to vasopressor selection in the critically ill.

Introduction: The Renin-Angiotensin-Aldosterone System and the Pathophysiology of Distributive Shock

The Renin-Angiotensin-Aldosterone System (RAAS)

The renin-angiotensin-aldosterone system (RAAS) is a critical hormonal cascade that regulates blood pressure, vascular resistance, and fluid and electrolyte balance.[1] The process is initiated when juxtaglomerular cells of the renal afferent arterioles release the enzyme renin in response to hypotension, sympathetic nervous stimulation, or decreased sodium delivery to the distal tubules.[3] Circulating renin cleaves its substrate, angiotensinogen (an α-2-globulin produced primarily by the liver), to form the decapeptide angiotensin I (Ang I).[3] Ang I possesses weak biological activity and serves as a precursor, which is rapidly converted to the potent octapeptide Angiotensin II (Ang II) by the action of angiotensin-converting enzyme (ACE), found predominantly in the endothelium of the lungs and other tissues.[1] Ang II is the principal effector of the RAAS, exerting powerful physiological effects, including systemic vasoconstriction, stimulation of aldosterone secretion from the adrenal cortex, and direct promotion of sodium and water reabsorption in the kidneys.[1]

Pathophysiology of Distributive Shock

Distributive shock represents a state of profound and life-threatening circulatory failure characterized by pathological vasodilation and increased capillary permeability, leading to a relative intravascular volume depletion and inadequate tissue perfusion.[3] Sepsis is the most common cause, accounting for approximately 90% of cases.[7] In this condition, despite a normal or often elevated cardiac output, the systemic vascular resistance is critically low, resulting in severe hypotension and organ dysfunction.[4]

The therapeutic rationale for administering exogenous Angiotensin II in distributive shock stems from the observation that the RAAS is often dysregulated in this state. During sepsis, factors such as endothelial dysfunction can impair ACE activity, leading to an accumulation of Ang I and a relative deficiency of Ang II.[10] This enzymatic bottleneck compromises one of the body's primary endogenous mechanisms for maintaining vascular tone. Consequently, patients may become refractory to standard catecholamine vasopressors (e.g., norepinephrine), which act on the sympathetic nervous system. The administration of synthetic Angiotensin II bypasses this compromised enzymatic step, directly stimulating the under-activated RAAS pathway. This represents a targeted physiological intervention designed to restore a specific failed homeostatic mechanism, rather than simply applying a non-specific vasoconstrictor.[3]

Distinction from RAAS Antagonists

It is imperative to distinguish Angiotensin II, a RAAS agonist, from the more commonly prescribed drug classes that act as RAAS antagonists. Angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril, ramipril) and Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan) are cornerstones in the management of chronic conditions like hypertension and heart failure.[12] These agents function by

inhibiting the effects of the RAAS to lower blood pressure. In stark contrast, the therapeutic Angiotensin II formulation (Giapreza) is the active hormone itself, administered to activate the RAAS and raise blood pressure in the acute, critical care setting of vasodilatory shock.[3]

Physicochemical Properties and Pharmaceutical Formulation

Chemical Identity

Angiotensin II is a synthetic human octapeptide hormone, meaning its chemical structure is identical to the naturally occurring peptide in the human body.[7] As a biotech therapeutic, it is produced through chemical synthesis rather than biological processes.[7] Its fundamental properties are well-defined, ensuring precise identification and characterization for pharmaceutical use.

Table 1: Key Identifiers and Physicochemical Properties of Angiotensin II

Property	Value / Description	Source(s)
International Nonproprietary Name	Angiotensin II	3
Brand Name	Giapreza®	3
DrugBank ID	DB11842	3
CAS Number	4474-91-3	3
PubChem CID	172198	23
Drug Type	Biotech; Peptide Hormone	3
Molecular Formula	C50​H71​N13​O12​	21
Average Molecular Weight	1046.18 Da	21
Amino Acid Sequence (1-Letter)	DRVYIHPF	1
Amino Acid Sequence (3-Letter)	Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH	1

Pharmaceutical Formulation (Giapreza®)

The commercial product, Giapreza, is formulated for intravenous administration in a critical care setting.[29]

• Formulation: Giapreza is a sterile, clear, and colorless aqueous solution of synthetic human Angiotensin II, which is present as an acetate salt.[29]
• Composition: Each milliliter of the concentrate contains 2.5 mg of Angiotensin II, 25 mg of mannitol as a stabilizing agent, and Water for Injection. The pH is adjusted to approximately 5.5 with sodium hydroxide and/or hydrochloric acid.[29]
• Presentation: It is supplied in single-dose, sterile glass vials as a concentrate for solution for infusion. Available presentations include 2.5 mg in 1 mL and 5 mg in 2 mL.[19]
• Physical Appearance: The active pharmaceutical ingredient is a white to off-white powder that is soluble in water.[1]

Preclinical and Clinical Pharmacology

Mechanism of Action

Angiotensin II exerts its physiological effects by binding to two primary subtypes of G-protein-coupled receptors: the Angiotensin II Type 1 (AT1) receptor and the Angiotensin II Type 2 (AT2) receptor.[3] The therapeutic pressor effect is mediated almost exclusively through the AT1 receptor.

• AT1 Receptor Pathway: Binding of Angiotensin II to AT1 receptors, which are densely expressed on vascular smooth muscle cells, initiates a signaling cascade. This involves the activation of phospholipase C and subsequent production of inositol triphosphate (IP3​), leading to the release of intracellular calcium (Ca2+).[24] The elevated intracellular calcium activates calmodulin, which in turn stimulates myosin light-chain kinase. This enzyme phosphorylates myosin, causing the contraction of smooth muscle cells and resulting in potent vasoconstriction.[3] In addition to vasoconstriction, AT1 receptor activation stimulates aldosterone secretion from the adrenal cortex, promotes sodium and water retention in the kidneys, and augments sympathetic nervous system activity.[12]
• AT2 Receptor Pathway: The effects mediated by the AT2 receptor are generally counter-regulatory to those of the AT1 receptor. AT2 receptor activation is associated with vasodilation, primarily through the production of nitric oxide and bradykinin, and exerts antiproliferative and cardiovascular protective effects.[12] In the context of administering Angiotensin II for shock, the overwhelming clinical effect is driven by the potent AT1-mediated vasoconstriction.

Pharmacodynamics

The primary pharmacodynamic effect of intravenously administered Angiotensin II is a rapid and dose-dependent increase in MAP.[3] This effect is predictable and titratable, making it suitable for managing hemodynamically unstable patients.

• Hemodynamic Effects: In the pivotal ATHOS-3 clinical trial, the median time to achieve the target MAP in responding patients was approximately 5 minutes, demonstrating a very rapid onset of action.[29] The effect on blood pressure is sustained throughout the continuous infusion.[35]
• Renal Effects: Angiotensin II induces vasoconstriction of both the afferent and efferent glomerular arterioles. However, its effect is more pronounced on the efferent arterioles. This differential action leads to a reduction in overall renal blood flow while simultaneously increasing the hydrostatic pressure within the glomerulus, thereby helping to maintain the glomerular filtration rate (GFR) in hypotensive states.[3]
• Endocrine Effects: The drug stimulates the synthesis and release of aldosterone from the zona glomerulosa of the adrenal cortex, which promotes sodium and water retention.[3] It also stimulates the secretion of vasopressin (antidiuretic hormone) from the posterior pituitary, further contributing to water retention and vasoconstriction.[3]

Pharmacokinetics

The pharmacokinetic profile of Angiotensin II is defined by its rapid action and extremely short duration, a profile that is both a therapeutic advantage and a practical constraint, dictating its exclusive use in the intensive care unit (ICU).

The extremely short half-life of less than one minute allows for precise, real-time control over a patient's blood pressure.[3] Doses can be titrated as frequently as every five minutes to achieve a specific MAP target without significant risk of prolonged overshoot or "stacking" of effects.[30] This rapid clearance also means that any adverse effects, such as excessive hypertension, can be quickly reversed by slowing or stopping the infusion.[7] However, this same property creates a significant clinical vulnerability. Any interruption in drug delivery, such as from a dislodged or failed peripheral intravenous line, would result in an immediate and potentially catastrophic loss of blood pressure support. For this reason, administration via a secure central venous line is strongly recommended to ensure patient safety.[17] This combination of properties inherently restricts its use to a high-acuity, continuously monitored environment.

Table 2: Summary of Pharmacokinetic Parameters of Intravenous Angiotensin II

Parameter	Value / Description	Source(s)
Administration Route	Continuous intravenous infusion	29
Time to Effect (Median)	~5 minutes	33
Plasma Half-life	< 1 minute	3
Metabolism	Rapidly degraded by peptidases (aminopeptidase A, ACE2) in plasma, erythrocytes, and major organs.	3
Key Metabolites	Angiotensin III (Ang-(2-8)), Angiotensin-(1-7)	3
Clearance	Not dependent on hepatic or renal function; no dose adjustment required for organ impairment.	3

Clinical Efficacy in Vasodilatory Shock

The clinical evidence supporting the use of Angiotensin II is dominated by the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial, which served as the basis for its regulatory approvals worldwide.

The ATHOS-3 Trial

• Study Design: ATHOS-3 was a landmark international, randomized, double-blind, placebo-controlled study conducted across 75 ICUs. It enrolled 321 adult patients with distributive shock (primarily septic shock) who remained hypotensive despite receiving adequate fluid resuscitation and high doses of conventional vasopressors, such as catecholamines and/or vasopressin.[16]
• Primary Endpoint: The trial's primary efficacy endpoint was the proportion of patients who achieved a MAP response at Hour 3 of treatment. This response was rigorously defined as either achieving a MAP of at least 75 mmHg or experiencing an increase in MAP of at least 10 mmHg from baseline, all without an increase in the dose of background vasopressor therapy.[37]
• Primary Endpoint Results: The study met its primary endpoint with a high degree of statistical significance. A MAP response at Hour 3 was achieved by 69.9% of patients in the Angiotensin II group, compared to only 23.4% of patients in the placebo group (Odds Ratio 7.95; 95% Confidence Interval [CI] 4.76–13.3; p<0.001).[11] This result unequivocally demonstrated the drug's potent and rapid hemodynamic effect in a refractory patient population.

Secondary and Exploratory Outcomes

• Vasopressor Sparing: A key secondary finding was the catecholamine-sparing effect of Angiotensin II. Over the first 48 hours, patients receiving Angiotensin II required consistently lower mean doses of background vasopressors to maintain their MAP target compared to those receiving placebo.[37]
• Organ Function: The trial also assessed changes in organ dysfunction using the Sequential Organ Failure Assessment (SOFA) score. At 48 hours, patients in the Angiotensin II group had a significantly greater improvement in the cardiovascular component of the SOFA score compared to the placebo group (mean change of -1.75 vs. -1.28; p=0.01).[38]
• Mortality: The trial was not powered to detect a difference in mortality. While there was a numerical trend favoring Angiotensin II, the difference in 28-day mortality was not statistically significant (46% in the Angiotensin II group vs. 54% in the placebo group; Hazard Ratio 0.78; 95% CI 0.57–1.07; p=0.12).[7]

Subgroup Analyses and Patient Phenotyping

The robust hemodynamic effect observed in ATHOS-3, paired with the neutral overall mortality outcome, prompted extensive post-hoc analyses to identify patient subgroups who might derive a greater benefit. These analyses have been instrumental in shaping the clinical understanding of where Angiotensin II may be most valuable. The findings suggest that the drug's utility may lie not as a universal agent for all shock patients, but as a precision therapy for specific, identifiable patient phenotypes.

This discrepancy between a strong effect on a surrogate endpoint (blood pressure) and a neutral effect on a hard endpoint (mortality) is a central clinical question. The answer appears to lie in patient selection. The post-hoc analyses suggest that in patients whose underlying pathophysiology aligns with the drug's mechanism—specifically, a dysregulated RAAS—a survival benefit emerges. This reframes Angiotensin II from a simple pressor to a targeted replacement therapy. This shift implies a future where vasopressor choice is not generic but guided by biomarkers, moving critical care towards a paradigm of precision medicine.

• Renin Levels: A pivotal exploratory analysis stratified patients by their baseline plasma renin activity. In the subgroup of patients with high renin levels (suggesting a hyper-reninemic state and a relative Angiotensin II deficiency), treatment with Angiotensin II was associated with a significantly lower 28-day mortality compared to placebo (51% vs. 70%; p=0.01).[37] This finding provides a strong biological rationale for using renin as a predictive biomarker.
• Acute Kidney Injury (AKI): In a subgroup of patients with AKI requiring renal replacement therapy (RRT), treatment with Angiotensin II was associated with improved survival and earlier liberation from RRT, suggesting a potential renal-protective effect in this high-risk population.[6]
• Timing of Initiation: Further exploratory analysis suggested that the timing of intervention is critical. Initiating Angiotensin II at lower doses of background vasopressors (norepinephrine equivalent dose ≤0.25 µg/kg/min) was associated with a higher likelihood of survival compared to initiating it later in the course of refractory shock.[37]

Table 3: Key Outcomes of the ATHOS-3 Clinical Trial

Outcome	Giapreza Arm (n=163)	Placebo Arm (n=158)	Result (Statistic, p-value)	Source(s)
Primary Endpoint: MAP Response at Hour 3	69.9% (114/163)	23.4% (37/158)	OR 7.95; p<0.001	38
28-Day All-Cause Mortality (Overall)	46% (75/163)	54% (85/158)	HR 0.78; p=0.12	33
Change in Cardiovascular SOFA Score at 48h	-1.75	-1.28	p=0.01	38
Serious Adverse Events	60.7%	67.1%	Not specified	38
28-Day Mortality (High Renin Subgroup)	51.1%	69.9%	p=0.01	42

Safety Profile, Tolerability, and Risk Management

The safety profile of Angiotensin II has been well-characterized through the ATHOS-3 trial and post-marketing surveillance. The most significant risk is thromboembolism, which requires active risk mitigation.

Adverse Event Profile

• Most Common Adverse Reaction: The most frequently reported adverse reaction, occurring in over 10% of patients treated with Giapreza, was thromboembolic events. In the ATHOS-3 study, these events occurred in 12.9% of patients in the Angiotensin II arm compared to 5.1% in the placebo arm.[16]
• Specific Thromboembolic Events: The primary driver of this imbalance was a higher incidence of deep vein thrombosis (DVT), which was reported in 4.3% of Angiotensin II-treated patients versus 0% of placebo-treated patients.[30]
• Other Clinically Relevant Events: Other adverse reactions reported more frequently with Angiotensin II than placebo (occurring in ≥4% of patients and ≥1.5% more often) included thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.[17]

Table 4: Adverse Reactions Occurring in ≥4% of Patients Treated with Giapreza and ≥1.5% More Often than Placebo in ATHOS-3

Adverse Event	Giapreza (N=163)	Placebo (N=158)	Source(s)
Thromboembolic events	12.9% (21)	5.1% (8)	30
Deep vein thrombosis	4.3% (7)	0.0% (0)	30
Thrombocytopenia	9.8% (16)	7.0% (11)	30
Tachycardia	8.6% (14)	5.7% (9)	30
Fungal infection	6.1% (10)	1.3% (2)	30
Delirium	5.5% (9)	0.6% (1)	30
Acidosis	5.5% (9)	0.6% (1)	30
Hyperglycemia	4.3% (7)	2.5% (4)	30
Peripheral ischemia	4.3% (7)	2.5% (4)	30

Warnings, Precautions, and Contraindications

• Primary Warning: The FDA-approved label includes a prominent warning regarding the potential for venous and arterial thrombotic and thromboembolic events.[30]
• Risk Mitigation: To mitigate this risk, the concurrent use of VTE prophylaxis (e.g., heparin or other anticoagulants) is mandatory for all patients receiving Giapreza, unless a specific contraindication to anticoagulation exists.[17]
• Contraindications: There are no absolute contraindications listed for the use of Giapreza.[16] The decision to use the drug is based on a risk-benefit assessment in the context of life-threatening shock.

Management of Overdose

An overdose of Angiotensin II would manifest as severe hypertension. Given the drug's extremely short plasma half-life of less than one minute, this effect is readily manageable. Treatment involves reducing the infusion rate or temporarily stopping the infusion, with supportive care and close hemodynamic monitoring. No specific antidote is necessary.[3]

Clinically Significant Drug Interactions

The drug interaction profile of Angiotensin II is mechanistically predictable but clinically important, particularly concerning common cardiovascular medications that also modulate the RAAS. A patient's home medication list can directly impact their response to this critical care drug, necessitating a careful medication history review prior to initiation.

• Angiotensin-Converting Enzyme (ACE) Inhibitors: Concomitant use of ACE inhibitors may increase the pressor response to exogenous Angiotensin II.[16] ACE inhibitors block the endogenous conversion of Ang I to Ang II, leading to an accumulation of Ang I and a loss of negative feedback on renin release. This "primes" the system, and when exogenous Ang II is administered, it acts on receptors that are not saturated by endogenous hormone, potentially leading to an exaggerated response.
• Angiotensin II Receptor Blockers (ARBs): Concomitant use of ARBs may decrease the pressor response to Angiotensin II.[3] ARBs are competitive antagonists at the AT1 receptor. When Giapreza is infused, it must compete with the ARB for the same binding sites, potentially requiring higher doses of Angiotensin II to achieve the desired hemodynamic effect.
• Other Vasoconstrictors: Certain other agents may have additive vasoconstrictive effects. Thyroid hormones (e.g., levothyroxine, liothyronine) and oxytocin have been noted to potentially increase the vasoconstricting activities of Angiotensin II.[3]

Clinical Application: Dosage, Administration, and Therapeutic Guidelines

Approved Indications

• U.S. Food and Drug Administration (FDA): Giapreza is indicated to increase blood pressure in adults with septic or other distributive shock.[3]
• European Medicines Agency (EMA): The indication is more specific, for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and the application of catecholamines and other available vasopressor therapies.[39]

Patient Selection

The intended patient population consists of adults with vasodilatory shock who are failing to respond adequately to standard therapies. This is often defined as requiring a norepinephrine equivalent dose greater than 0.2 µg/kg/min.[17] A prerequisite for initiation is that the patient has been adequately fluid-resuscitated, as vasopressors are not a substitute for volume replacement.[17]

Dosage and Titration

• Starting Dose: The recommended initial dosage is 20 ng/kg/min administered via continuous intravenous infusion.[30]
• Titration: The dose should be titrated rapidly to effect. The infusion rate can be adjusted as frequently as every 5 minutes by increments of up to 15 ng/kg/min to achieve or maintain the target MAP.[32]
• Maximum Dose: During the first 3 hours of treatment, the dose should not exceed 80 ng/kg/min. The maintenance dose should not exceed 40 ng/kg/min.[30]
• Maintenance: Doses as low as 1.25 ng/kg/min may be sufficient to maintain blood pressure once stabilized.[32]
• Weaning: As the underlying shock state resolves, the infusion should be weaned by down-titrating in decrements of up to 15 ng/kg/min every 5 to 15 minutes as tolerated.[29]

Administration

• Preparation: Giapreza is a concentrate that must be diluted in 0.9% sodium chloride prior to administration. The final concentration should be either 5,000 ng/mL or 10,000 ng/mL. The higher concentration is intended for fluid-restricted patients.[29]
• Route of Administration: The diluted solution must be administered as a continuous intravenous infusion. Due to the potent vasoconstrictive effects and the critical need for uninterrupted delivery, administration through a central venous line is strongly recommended.[17]
• Storage and Stability: Unopened vials of Giapreza must be stored under refrigeration at 2°C to 8°C (36°F to 46°F). The prepared, diluted solution is stable for up to 24 hours at either room temperature or under refrigeration.[29]

Comparative Analysis: Angiotensin II in the Modern Vasopressor Armamentarium

The introduction of Angiotensin II has expanded the options for managing refractory shock, shifting the paradigm from a linear escalation of catecholamines to a more balanced, multi-mechanistic approach. Its unique mechanism of action complements existing vasopressors, allowing for a strategy that targets the three core pressor systems of the body: the sympathetic nervous system, the vasopressinergic system, and the RAAS. This enables a more physiologically complete resuscitation, potentially using lower doses of each agent to minimize class-specific toxicities while achieving hemodynamic goals.

Table 5: Comparative Profile of Vasopressors Used in Distributive Shock

Agent	Mechanism of Action	Primary Hemodynamic Effects	Key Adverse Effects	Place in Therapy
Norepinephrine	Strong α1-adrenergic agonist, moderate β1-adrenergic agonist	Potent vasoconstriction, modest increase in cardiac output	Tachyarrhythmias, peripheral/splanchnic ischemia, hyperglycemia	First-line agent for septic and other distributive shock 48
Vasopressin	V1 receptor agonist (non-adrenergic)	Potent vasoconstriction, particularly in splanchnic circulation	Peripheral/digital ischemia, splanchnic ischemia, decreased cardiac output	Second-line agent, added to norepinephrine as a catecholamine-sparing therapy 48
Epinephrine	Potent α1, β1, and β2-adrenergic agonist	Potent vasoconstriction, significant increase in cardiac output and heart rate	Tachyarrhythmias, hyperglycemia, increased lactate levels, myocardial ischemia	Second or third-line agent, added to norepinephrine, particularly if inotropy is needed 48
Angiotensin II	AT1 receptor agonist (non-adrenergic)	Potent systemic vasoconstriction, stimulates aldosterone release	Thromboembolism (arterial and venous), peripheral ischemia, tachycardia	Approved for shock refractory to other vasopressors; may be considered a second or third-line agent 3

• Versus Norepinephrine: Norepinephrine remains the undisputed first-line vasopressor for distributive shock.[52] Angiotensin II is not a replacement but an adjunctive therapy for patients who are refractory to norepinephrine. Its primary role is to restore blood pressure when the catecholamine pathway is exhausted or desensitized, thereby allowing for a reduction in norepinephrine dosage and potentially mitigating catecholamine-associated toxicities like tachyarrhythmias.[40]
• Versus Vasopressin: Vasopressin is the established second-line non-catecholamine vasopressor.[48] The rationale for using both vasopressin and Angiotensin II is similar: to engage a non-adrenergic pressor system as a catecholamine-sparing strategy.[55] Clinical trials are underway to directly compare Angiotensin II with vasopressin as the preferred second-line agent.[56] A theoretical concern is the potential for severe peripheral or splanchnic ischemia when three potent vasoconstrictors (norepinephrine, vasopressin, and Angiotensin II) are used concurrently.[55]
• Versus Epinephrine: Epinephrine is generally reserved as a later-line agent or for patients with concomitant cardiac dysfunction requiring inotropic support.[48] A retrospective, propensity-matched study comparing third-line Angiotensin II to third-line epinephrine found no significant difference in clinical response or mortality, although the study was underpowered to detect such differences.[57]

Regulatory, Manufacturing, and Commercial Landscape

Global Regulatory Approval History

• U.S. Food and Drug Administration (FDA): Angiotensin II was approved on December 21, 2017, under the brand name Giapreza. The application, submitted for the drug candidate then known as LJPC-501, was granted a priority review, reflecting the significant unmet need for new therapies in refractory shock.[7] A historically related product, bovine angiotensin (Hypertensin®), which differs by one amino acid, was approved in 1962 but is no longer marketed.[7]
• European Medicines Agency (EMA): Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2019, Giapreza received marketing authorization valid throughout the European Union on August 23, 2019.[39]

Intellectual Property and Patent Exclusivity

The commercial longevity of Giapreza is protected by a robust portfolio of intellectual property. Multiple patents, primarily assigned to The George Washington University, cover specific methods of use, including dosing regimens for treating hypotension in various shock states.[62] These key patents have expiration dates extending into the 2030s (e.g., 2029 and 2034), providing a long period of market exclusivity.[62] Although a generic version from Gland Pharma has received FDA approval with a future date, its commercial launch will likely be contingent on the expiration or resolution of these patents.[62]

Manufacturing, Marketing, and Commercialization

• Originator and Developer: The drug was developed by La Jolla Pharmaceutical Company.[64]
• Commercial Entities: In the United States, Giapreza is currently marketed by Innoviva Specialty Therapeutics.[58] In Europe, an exclusive licensing agreement for marketing and distribution is held by PAION AG.[64]
• Manufacturing Process: Giapreza is a synthetic peptide, meaning it is produced through chemical synthesis rather than recombinant DNA technology.[3] La Jolla Pharmaceutical does not operate its own manufacturing facilities but relies on third-party contract manufacturing organizations (CMOs) that must adhere to current Good Manufacturing Practices (cGMPs).[67] The synthesis of an octapeptide like Angiotensin II typically employs Solid-Phase Peptide Synthesis (SPPS). This well-established method involves the sequential coupling of protected amino acids to a growing peptide chain anchored to an insoluble resin support, followed by cleavage from the resin and extensive purification, commonly using high-performance liquid chromatography (HPLC) to achieve pharmaceutical-grade purity.[68]

Future Perspectives and Investigational Horizons

Research into Angiotensin II and the broader RAAS continues to evolve, with ongoing studies aiming to refine its clinical role and explore new therapeutic applications. The current clinical trial landscape reflects a strategic evolution from establishing efficacy in the most critically ill patients to defining its optimal use earlier in treatment and across different clinical scenarios. This progression represents a shift from a "salvage therapy" to a more integrated component of critical care for specific indications.

Review of Ongoing and Recently Completed Clinical Trials

Angiotensin II is being actively investigated in several clinical settings beyond its initial indication for refractory distributive shock. These trials are crucial for expanding its evidence base and defining its place in therapy.

Table 6: Summary of Ongoing and Recently Completed Clinical Trials for Giapreza®

ClinicalTrials.gov ID	Trial Title / Acronym	Phase	Status	Condition / Indication	Brief Summary of Purpose
NCT06487585	ANG-First Trial	4	Recruiting	Hypotension After Cardiac Surgery	To evaluate Angiotensin II as a first-line vasopressor therapy for postoperative hypotension in cardiac surgery patients.71
NCT04901169	AngLT-1	2/3	Recruiting	Vasoplegia during Liver Transplantation	To determine the efficacy and safety of Angiotensin II as a second-line vasopressor during liver transplantation.72
NCT03733145	Angiotensin II in General Anesthesia	Not Applicable	Completed	Anesthesia-Mediated Hypotension	A dose-finding trial to determine the effective infusion rate of Angiotensin II for hypotension in hypertensive patients on ACEi/ARBs.73
NCT03302650	Angiotensin II for Septic Shock Treatment	Not Applicable	Completed	Septic Shock	To investigate the effect of Angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.74

The Potential for Biomarker-Guided Therapy

Perhaps the most significant future direction for Angiotensin II is the development of a biomarker-guided treatment strategy. The compelling post-hoc finding from ATHOS-3, which showed a substantial mortality benefit in patients with high baseline renin levels, provides a strong rationale for this approach.[37] If validated prospectively, plasma renin activity could be used as a diagnostic tool to identify patients with a dysregulated RAAS who are most likely to respond favorably to Angiotensin II. This would represent a major advance in critical care, shifting vasopressor selection from a generalized algorithm to a personalized, mechanism-based choice, thereby improving outcomes and enhancing the cost-effectiveness of this high-cost therapy.[11]

Emerging Therapeutic Indications and Research Frontiers

• Broader RAAS Modulation: The RAAS is a complex system with multiple bioactive peptides. Beyond Angiotensin II, there is growing research interest in the therapeutic potential of other components. Angiotensin-(1-7), a metabolite of Angiotensin II, exerts protective, vasodilatory, and anti-inflammatory effects via the Mas receptor, making it a target for conditions like diabetes and asthma.[2] Similarly, selective AT2 receptor agonists, such as the investigational compound C21, are being explored for their anti-inflammatory and tissue-protective properties.[76]
• New Indications for Angiotensin II: Based on its mechanism and preliminary evidence, Angiotensin II may have a role in other shock states characterized by vasodilation or RAAS disruption. These include cardiogenic shock, post-cardiac surgery vasoplegia, liver failure-associated hypotension, and managing hypotension from ACE inhibitor overdose.[6]

Conclusion and Strategic Recommendations

Angiotensin II (Giapreza®) is a potent, mechanistically distinct vasopressor that serves as a vital addition to the critical care armamentarium. Its efficacy in rapidly and reliably increasing mean arterial pressure in patients with distributive shock refractory to conventional therapies is well-established. It functions as a direct RAAS agonist, offering a catecholamine-sparing effect that aligns with modern, multimodal resuscitation strategies.

This proven hemodynamic benefit must be carefully balanced against a significant and clinically important risk of thromboembolic events, which mandates concurrent VTE prophylaxis. Furthermore, while a definitive mortality benefit has not been demonstrated in the overall refractory shock population, compelling evidence from subgroup analyses suggests that patients with specific phenotypes, particularly those with a hyper-reninemic state, may derive a substantial survival advantage.

• Strategic Recommendations for Clinicians: The use of Angiotensin II should be reserved for patients with distributive shock who remain hypotensive despite adequate fluid resuscitation and escalating doses of first-line vasopressors. Clinicians must adhere strictly to the recommended dosing, titration, and central line administration protocols. The mandatory implementation of VTE prophylaxis is paramount to patient safety. Consideration should be given to earlier initiation in patients with clinical features suggestive of a high-renin state or those developing acute kidney injury.
• Strategic Recommendations for Researchers: The highest priority for future research is the prospective validation of a biomarker-guided approach. A large-scale, randomized controlled trial is urgently needed to confirm whether stratifying patients by plasma renin activity can identify a population in whom Angiotensin II improves survival. Additionally, head-to-head trials comparing Angiotensin II to vasopressin as the preferred second-line, non-catecholamine agent are required to clarify the optimal vasopressor sequence.
• Strategic Recommendations for Healthcare Systems: The high acquisition cost of Giapreza necessitates a careful cost-benefit analysis. Its value is maximized when used in a targeted manner. If future studies confirm its benefit in specific subgroups, its use could prove cost-effective by reducing the duration of ICU stays, decreasing the need for renal replacement therapy, and improving survival in select patients.

In conclusion, Giapreza represents a specialized but powerful therapeutic tool. Its ultimate impact on critical care will depend on the successful translation of promising subgroup findings into routine, biomarker-guided clinical practice, heralding a potential new era of personalized medicine in the management of shock.

Works cited

1. Angiotensin II | 4474-91-3 - Isca Biochemicals, accessed August 6, 2025, https://www.iscabiochemicals.com/products/0/227
2. Angiotensin-(1-7) and Mas receptor in the brain - Open Exploration Publishing, accessed August 6, 2025, https://www.explorationpub.com/index.php/Journals/em/Article/100146
3. Angiotensin II: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB11842
4. Angiotensin II—Real-Life Use and Literature Review - MDPI, accessed August 6, 2025, https://www.mdpi.com/1648-9144/60/9/1483
5. Preclinical Pharmacology of Angiotensin II Receptor Antagonists: Update and Outstanding Issues - Oxford Academic, accessed August 6, 2025, https://academic.oup.com/ajh/article/10/S9/306S/131531
6. Angiotensin II: a new therapeutic option for vasodilatory shock - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6067786/
7. 209360Orig1s000 - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209360Orig1s000SumR.pdf
8. Distributive Shock - StatPearls - NCBI Bookshelf, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK470316/
9. Vasopressor Therapy - MDPI, accessed August 6, 2025, https://www.mdpi.com/2077-0383/13/23/7372
10. Why GIAPREZA® (angiotensin II), accessed August 6, 2025, https://www.giapreza.com/why
11. The Case for Angiotensin II in Vasodilatory Shock Patients Gathers More Steam, accessed August 6, 2025, https://consultqd.clevelandclinic.org/the-case-for-angiotensin-ii-in-vasodilatory-shock-patients-gathers-more-steam
12. Angiotensin II Receptor Blockers (ARB) - StatPearls - NCBI Bookshelf, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537027/
13. Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10307051/
14. Angiotensin-Converting Enzyme (ACE) Inhibitors - Cleveland Clinic, accessed August 6, 2025, https://my.clevelandclinic.org/health/treatments/21934-ace-inhibitors
15. Angiotensin receptor blockers (ARBs) - Heart Matters magazine - BHF, accessed August 6, 2025, https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/drug-cabinet/arbs
16. GIAPREZA® (angiotensin II): For Healthcare Professionals, accessed August 6, 2025, https://www.giapreza.com/
17. Angiotensin II - StatPearls - NCBI Bookshelf, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK499912/
18. Angiotensin II (medication) - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Angiotensin_II_(medication)
19. Giapreza 4930 - EPAR - EMA, accessed August 6, 2025, https://www.ema.europa.eu/en/documents/assessment-report/giapreza-epar-public-assessment-report_en.pdf
20. angiotensin II | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 6, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504
21. Angiotensin II, Human | CAS 4474-91-3 | SCBT, accessed August 6, 2025, https://www.scbt.com/p/angiotensin-ii-human-4474-91-3
22. Angiotensin II (human) 5 mg | Buy Online | Thermo Scientific Chemicals | thermofisher.com, accessed August 6, 2025, https://www.thermofisher.com/order/catalog/product/J60866.LB0
23. Angiotensin II | Non-selective AT Receptors - Tocris Bioscience, accessed August 6, 2025, https://www.tocris.com/products/angiotensin-ii_1158
24. Angiotensin II (human), Vasoconstrictor peptide (AB120183) - Abcam, accessed August 6, 2025, https://www.abcam.com/en-us/products/biochemicals/angiotensin-ii-human-vasoconstrictor-peptide-ab120183
25. Angiotensin Ii | C50H71N13O12 | CID 172198 - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Human-angiotensin-II
26. Angiotensin II, human - Echelon Biosciences, accessed August 6, 2025, https://www.echelon-inc.com/product/angiotensin-ii-human/
27. angiotensin II - PharmGKB, accessed August 6, 2025, https://www.pharmgkb.org/chemical/PA166109554
28. Angiotensin II human | Ang II | vasoconstrictor - TargetMol, accessed August 6, 2025, https://www.targetmol.com/compound/angiotensin%20ii%20human
29. Giapreza: Package Insert / Prescribing Information - Drugs.com, accessed August 6, 2025, https://www.drugs.com/pro/giapreza.html
30. Reference ID: 4199496 This label may not be the latest approved by ..., accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf
31. Package leaflet: Information for the patient Giapreza 2.5 mg/ml concentrate for solution for infusion angiotensin II This medici, accessed August 6, 2025, https://www.medicines.org.uk/emc/files/pil.13868.pdf
32. Giapreza (synthetic human angiotensin II) dosing, indications ..., accessed August 6, 2025, https://reference.medscape.com/drug/giapreza-synthetic-human-angiotensin-ii-1000206
33. 209360Orig1s000 | FDA, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209360Orig1s000lbl.pdf
34. Using GIAPREZA® (angiotensin II) | Dosing and Administration, accessed August 6, 2025, https://www.giapreza.com/using-giapreza
35. GIAPREZA, INN-angiotensin II actetate, accessed August 6, 2025, https://ec.europa.eu/health/documents/community-register/2021/20210527151975/anx_151975_en.pdf
36. Giapreza: A Look at the Pharmacology of Ang2 - Pharmacy Times, accessed August 6, 2025, https://www.pharmacytimes.com/view/giapreza-a-look-at-the-pharmacology-of-ang2
37. Efficacy and Trial Design | GIAPREZA® (angiotensin II), accessed August 6, 2025, https://www.giapreza.com/efficacy
38. FDA approves angiotensin II formulation (Giapreza) for blood pressure maintenance in adults with refractory septic shock - Escavo, accessed August 6, 2025, https://escavo.com/2017/12/22/fda-approves-angiotensin-ii-giapreza-increase-blood-pressure-adults-refractory-septic-shock/
39. Giapreza | European Medicines Agency (EMA), accessed August 6, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza
40. A Multicenter Observational Cohort Study of Angiotensin II in Shock - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8559525/
41. Clinical Outcomes of Angiotensin II Therapy in Vasoplegic Shock: A Systematic Review and Meta-Analysis - MDPI, accessed August 6, 2025, https://www.mdpi.com/2075-1729/14/9/1085
42. Angiotensin II in Treating Vasodilatory Shock | OAEM - Dove Medical Press, accessed August 6, 2025, https://www.dovepress.com/how-effective-is-angiotensin-ii-in-decreasing-mortality-of-vasodilator-peer-reviewed-fulltext-article-OAEM
43. Adjunctive vasopressors in distributive shock: How soon is early? - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10230760/
44. Safety & Adverse Events | GIAPREZA® (angiotensin II), accessed August 6, 2025, https://www.giapreza.com/safety
45. GIAPREZA (ANGIOTENSIN II) INJECTION, accessed August 6, 2025, https://dosing.giapreza.com/www.fda.gov/medwatch
46. Giapreza Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 6, 2025, https://www.drugs.com/sfx/giapreza-side-effects.html
47. Justification, accessed August 6, 2025, https://www.g-ba.de/downloads/40-1465-8160/2022-01-06_AM-RL-XII_Angiotensin-II_D-711_TrG_EN.pdf
48. Vasopressors in septic shock: which, when, and how much? - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7333107/
49. Vasopressors During Sepsis: Selection and Targets - Department of Anesthesiology » College of Medicine », accessed August 6, 2025, https://anest.ufl.edu/wordpress/files/2021/07/vasopressor-choice-in-sepsis-review.pdf
50. “Pressors” in Distributive Shock in Adults - Maimonides Emergency Medicine Residency, accessed August 6, 2025, https://www.maimonidesem.org/blog/pressors-in-distributive-shock-in-adults
51. What is the treatment for refractory distributive shock? - Dr.Oracle, accessed August 6, 2025, https://www.droracle.ai/articles/91899/how-do-you-treat-refractory-distributive-shock
52. What is the comparative strength of vasopressin (Vasopressin) receptor agonism versus alpha (α) receptor agonism induced by norepinephrine (Norepinephrine) on blood pressure regulation? - Dr.Oracle, accessed August 6, 2025, https://www.droracle.ai/articles/70034/how-strong-is-vasopressin-receptor-agonism-vs-alpha-receptor-agonism-induced-by-norepinephrine-for-blood-pressure-
53. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis | PLOS One - Research journals, accessed August 6, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129305
54. (PDF) Angiotensin II therapy in refractory septic shock: which patient can benefit most? A narrative review - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/378369278_Angiotensin_ii_therapy_in_refractory_septic_shock_which_patient_can_benefit_most_A_narrative_review
55. PulmCrit- Angiotensin II: five cautions & three comparisons, accessed August 6, 2025, https://emcrit.org/pulmcrit/angiotensin-ii/
56. Study Details | Angiotensin II vs. Vasopressin in Septic Shock | ClinicalTrials.gov, accessed August 6, 2025, https://www.clinicaltrials.gov/study/NCT05193370
57. Clinical Response to Third-Line Angiotensin-II vs Epinephrine in ..., accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/38303571/
58. Giapreza (angiotensin II) FDA Approval History - Drugs.com, accessed August 6, 2025, https://www.drugs.com/history/giapreza.html
59. With La Jolla's $500M Giapreza nod, FDA breaks a high-water mark for approvals, accessed August 6, 2025, https://www.fiercepharma.com/regulatory/as-la-jolla-s-giapreza-wins-approval-fda-passes-recent-high-water-mark
60. EU Panel Backs Angiotensin II (Giapreza) for Septic Shock - Medscape, accessed August 6, 2025, https://www.medscape.com/viewarticle/915044
61. Human medicines European public assessment report (EPAR): Giapreza, angiotensin II, Date of authorisation: 23/08/2019, Revision: 4, Status - EIN Presswire, accessed August 6, 2025, https://www.einpresswire.com/article/717773073/human-medicines-european-public-assessment-report-epar-giapreza-angiotensin-ii-date-of-authorisation-23-08-2019-revision-4-status-authorised
62. Generic Giapreza Availability - Drugs.com, accessed August 6, 2025, https://www.drugs.com/availability/generic-giapreza.html
63. US10028995B2 - Angiotensin II alone or in combination for the treatment of hypotension - Google Patents, accessed August 6, 2025, https://patents.google.com/patent/US10028995B2/en
64. Angiotensin II - La Jolla Pharmaceutical Company - AdisInsight - Springer, accessed August 6, 2025, https://adisinsight.springer.com/drugs/800037647
65. La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019 - BioSpace, accessed August 6, 2025, https://www.biospace.com/la-jolla-pharmaceutical-company-announces-preliminary-giapreza-angiotensin-ii-net-sales-for-the-three-and-twelve-months-ended-december-31-2019
66. La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe - Business Wire, accessed August 6, 2025, https://www.businesswire.com/news/home/20210112005460/en/La-Jolla-Pharmaceutical-Company-Announces-Exclusive-Licensing-Agreement-for-GIAPREZA-Angiotensin-II-and-XERAVA-Eravacycline-in-Europe
67. la jolla pharmaceutical company - SEC.gov, accessed August 6, 2025, https://www.sec.gov/Archives/edgar/data/920465/000092046520000036/ljpc-201910xk.htm
68. Advances in Peptide Synthesis: From Fundamentals to Innovative Strategies, accessed August 6, 2025, https://www.openaccessjournals.com/articles/advances-in-peptide-synthesis-from-fundamentals-to-innovative-strategies-16823.html
69. Chemical Methods for Peptide and Protein Production - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6270108/
70. Step-by-step guide to peptide synthesis and manufacturing: From discovery to production, accessed August 6, 2025, https://www.sterlingpharmasolutions.com/knowledge-hub/peptides/peptide-synthesis-and-production-from-discovery-to-manufacturing/
71. Study Details | ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery) | ClinicalTrials.gov, accessed August 6, 2025, https://clinicaltrials.gov/study/NCT06487585?term=AREA%5BConditionSearch%5D(%22Vascular%20Disease%22)%20AND%20AREA%5BInterventionSearch%5D(%22giapreza%22)&rank=8
72. Study Details | Angiotensin II in Liver Transplantation - ClinicalTrials.gov, accessed August 6, 2025, https://clinicaltrials.gov/study/NCT04901169
73. Study Details | Angiotensin II in General Anesthesia - ClinicalTrials.gov, accessed August 6, 2025, https://www.clinicaltrials.gov/study/NCT03733145?term=AREA%5BBasicSearch%5D(Angiotensin%20II%20receptor)&rank=1
74. Study Details | Angiotensin II for Septic Shock Treatment | ClinicalTrials.gov, accessed August 6, 2025, https://clinicaltrials.gov/study/NCT03302650?term=NCT01393782%20NCT03302650&rank=1
75. The therapeutic potential of angiotensin-(1–7) | Request PDF - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/369008912_The_therapeutic_potential_of_angiotensin-1-7
76. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB | Hypertension, accessed August 6, 2025, https://www.ahajournals.org/doi/10.1161/hypertensionaha.109.147843
77. Angiotensin II: a new therapeutic option for vasodilatory shock | TCRM - Dove Medical Press, accessed August 6, 2025, https://www.dovepress.com/angiotensin-ii-a-new-therapeutic-option-for-vasodilatory-shock-peer-reviewed-fulltext-article-TCRM